This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The study designs were not reported. The authors stated that more recent German studies were preferred over older studies published abroad.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
The effective evidence was derived from 28 primary studies.
Methods of combining primary studies
The primary studies were not combined. 
Investigation of differences between primary studies
Results of the review
In patients who relapse, the estimated probability values were: 
Methods used to derive estimates of effectiveness
The authors made some assumptions due to the lack of data derived from the literature.
Estimates of effectiveness and key assumptions
When the data were unavailable, the authors made conservative assumptions, assuming that the same probability values applied to both abstinent and relapsed patients. In other cases, a probability value of zero was used for abstinent patients.
Measure of benefits used in the economic analysis
The benefit measure used in the economic analysis was the number of life-years gained with adjuvant acamprosate over standard therapy. It was modelled, and a 5% discount rate was used.
